Scotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its price target decreased by research analysts at Scotiabank from $77.00 to $44.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a "sector outperform" rating on the stock. Scotiabank's target price would indicate a potential upside of 133.67% from the company's current price.

Several other equities research analysts have also issued reports on KROS. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a report on Thursday, September 12th. Wells Fargo & Company upped their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an "overweight" rating in a research note on Wednesday. William Blair downgraded Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating for the company. Finally, TD Cowen downgraded Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $85.67.

Keros Therapeutics Trading Up 2.2 %

NASDAQ:KROS traded up $0.40 during trading hours on Friday, hitting $18.83. 5,182,908 shares of the company traded hands, compared to its average volume of 457,177. The stock has a market capitalization of $762.75 million, a price-to-earnings ratio of -3.61 and a beta of 1.20. The firm has a 50-day moving average of $59.11 and a 200 day moving average of $52.65. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business's revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.33) EPS. Equities research analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its position in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new stake in Keros Therapeutics during the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics during the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the 3rd quarter valued at about $213,000. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.